prikaz prve stranice dokumenta Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial
Access restricted to all Croatian higher education institution's students and staff
Scientific paper - Original scientific paper
Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial
Diabetes, Obesity and Metabolism, 22 (2020), 11; 2097-2106. https://doi.org/10.1111/dom.14129
Lukenda Žanko, Vesna; Domislović, Viktor; Trkulja, Vladimir; Krznarić-Zrnić, Irena; Turk-Wensveen, Tamara; Krznarić, Željko; Filipec Kanižaj, Tajana; Radić-Kristo, Delfa; Bilić-Zulle, Lidija; Orlić, Lidija; Dinjar-Kujundžić, Petra; Poropat, Goran; Štimac, Davor; Hauser, Goran; Mikolašević, Ivana More authors...

Cite this document

Lukenda Žanko, V., Domislović, V., Trkulja, V., Krznarić Zrnić, I., Turk Wensveen, T., Krznarić, Ž. ... Mikolašević, I. (2020). Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial. Diabetes, Obesity and Metabolism, 22. (11), 2097-2106. doi: 10.1111/dom.14129

Lukenda Žanko, Vesna, et al. "Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial." Diabetes, Obesity and Metabolism, vol. 22, no. 11, 2020, pp. 2097-2106. https://doi.org/10.1111/dom.14129

Lukenda Žanko, Vesna, Viktor Domislović, Vladimir Trkulja, Irena Krznarić Zrnić, Tamara Turk Wensveen, Željko Krznarić, Tajana Filipec Kanižaj, et al. "Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial." Diabetes, Obesity and Metabolism 22, no. 11 (2020): 2097-2106. https://doi.org/10.1111/dom.14129

Lukenda Žanko, V., et al. (2020) 'Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial', Diabetes, Obesity and Metabolism, 22(11), pp. 2097-2106. doi: 10.1111/dom.14129

Lukenda Žanko V, Domislović V, Trkulja V, Krznarić Zrnić I, Turk Wensveen T, Krznarić Ž, and sur.. Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial. Diabetes, Obesity and Metabolism [Internet]. 2020 [cited 2024 November 25];22(11):2097-2106. doi: 10.1111/dom.14129

V. Lukenda Žanko, et al., "Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial", Diabetes, Obesity and Metabolism, vol. 22, no. 11, pp. 2097-2106, 2020. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:716459. [Accessed: 25 November 2024]

Please login to the repository to save this object to your list.
Metadata
Title (english)Vitamin D for treatment of non-alcoholic fatty liver disease detected by transient elastography: A randomized, double-blind, placebo-controlled trial
AuthorVesna Lukenda Žanko
AuthorViktor Domislović
AuthorVladimir Trkulja
AuthorIrena Krznarić-Zrnić
AuthorTamara Turk-Wensveen
AuthorŽeljko Krznarić
AuthorTajana Filipec Kanižaj
AuthorDelfa Radić-Kristo
AuthorLidija Bilić-Zulle
AuthorLidija Orlić
AuthorPetra Dinjar-Kujundžić
AuthorGoran Poropat
AuthorDavor Štimac
AuthorGoran Hauser
AuthorIvana Mikolašević
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Internal Medicine)
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Medical Informatics)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Abstract Aim: To evaluate the effects of vitamin D on transient elastography (TE, FibroScan) indices of liver steatosis (controlled attenuation parameter [CAP]) and fibrosis (liver stiffness measurement [LSM]) in adults with non-alcoholic fatty liver disease (NAFLD). Patients and methods: In this randomized (2:1), double-blind, single-centre, 12-month trial, patients with NAFLD were treated with vitamin D (1000 IU/day) (n = 201) or a matching placebo (n = 110). Two co-primary outcomes were changes in CAP and LSM after 360 days of treatment versus baseline. Two main secondary outcomes were CAP/LSM changes after 180 days of treatment. Results: Both CAP and LSM gradually decreased in vitamin D-treated patients and slightly increased in the placebo arm. Vitamin D was superior to placebo for both primary outcomes (mean differences in CAP and LSM changes (-49.5 dB/m [95% CI -59.5 to -39.4] and -0.72 kPa [95% CI -1.43 to 0.00], respectively) and both secondary outcomes (-22.1 dB/m [-32.1 to -12.1] and -0.89 kPa [-1.61 to -0.17], respectively). Of a number of exploratory outcomes (change at 12 months vs. baseline), vitamin D reduced serum uric acid (-17.9 μmol/L [-30.6 to -5.2]), gamma-glutamyltransferase (-8.9 IU/L [-15.5 to -2.3)] and fasting serum insulin levels (-5.1 pmol/L [-9.3 to -0.8]) as well as the homeostatic model assessment of insulin resistance index (-1.6 [-3.1 to -0.2]) (false discovery rate [5%]-adjusted P-values between .0572 and .0952). Conclusion: Low-medium dose supplementation of vitamin D (1000 IU/day) over 12 months reduces TE indices of liver steatosis (CAP) and fibrosis (LSM) in NAFLD patients.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleDiabetes, Obesity and Metabolism
Numberingvol. 22, no. 11, pp. 2097-2106
p-ISSN1462-8902
e-ISSN1463-1326
DOIhttps://doi.org/10.1111/dom.14129
URN:NBNurn:nbn:hr:184:716459
Publication2020
Document URLhttp://bib.irb.hr/1088454
Type of resourceText
Access conditionsRestricted access
Terms of useLicence In copyright icon
Created on2022-03-14 14:09:24